Hyperkalemia

Descriptive text is not available for this image Basics

Description

  • An electrolyte disorder defined as a plasma potassium (K) concentration >5.5 mEq/L (>5 mmol/L)
  • Hyperkalemia depresses cardiac conduction and can lead to fatal arrhythmias.
  • Normal K regulation involves tightly coordinated mechanisms:
    • After ingestion, K enters the portal circulation, stimulating pancreatic insulin release, which promotes entry of K into cells.
    • In the kidneys, K stimulates renin release from juxtaglomerular cells, activating the renin-angiotensin-aldosterone system (RAAS). Angiotensin II in the lungs stimulates aldosterone secretion from the adrenal zona glomerulosa. Aldosterone acts on the renal collecting ducts to enhance K excretion and sodium reabsorption.
  • Four major causes
    • Increased load: either endogenous from tissue breakdown (i.e., rhabdomyolysis or hemolysis) or exogenous (dietary or iatrogenic), usually in association with impaired renal function due to chronic kidney disease (CKD)
    • Decreased excretion (most common): due to reduced glomerular filtration rate or impaired aldosterone secretion
    • Cellular redistribution: shifts from intracellular space (majority of K is intracellular) to extracellular space (as in metabolic acidosis, tissue injury)
    • Pseudohyperkalemia: artificial elevation of K due to hemolysis of blood sample, thrombocytosis, or leukocytosis

Geriatric Considerations
Increased risk for hyperkalemia because of decline in renin and aldosterone production with age, which impairs renal K excretion, especially in the setting of comorbid conditions

Epidemiology

Prevalence

  • 5–9% of hospitalized patients (1)
  • 1–2% in general population but as high as 34% in patients with CKD

Etiology and Pathophysiology

  • Impaired K excretion (most common)
    • Renal insufficiency/failure, obstructive uropathy
    • Addison disease
    • Mineralocorticoid deficiency
    • Type IV renal tubular acidosis
    • Cirrhosis
    • Congestive heart failure
    • Sickle cell disease
    • Amyloidosis
    • Systemic lupus erythematosus
  • Increased K intake (2)
    • Bananas, potatoes, melons, citrus juice, avocados, red meat, nuts, and dried fruits
    • Salt substitutes given to CKD patients
  • Transcellular shift (redistribution)
    • Metabolic acidosis
    • Insulin deficiency
    • Hyperglycemia (diabetic ketoacidosis or hyperosmolar hyperglycemic state)
    • Tissue damage (rhabdomyolysis, tumor lysis syndrome, burns, trauma)
  • Medication-induced (3)
    • RAAS inhibitors
    • K-sparing diuretics
    • NSAIDs
    • Heparin
    • Trimethoprim
    • β-Blockers
  • Pseudohyperkalemia
    • Hemolysis of blood sample (artifactual)
    • Thrombolysis, thrombocytosis, leukocytosis
    • Hereditary spherocytosis
    • Infectious mononucleosis
    • Familial pseudohyperkalemia

Genetics

Associated with some inherited diseases and conditions

  • Familial hyperkalemic periodic paralysis
  • Congenital adrenal hyperplasia
  • Gordon syndrome

Risk Factors

  • Impaired renal excretion of K
  • Acidemia
  • Massive cell breakdown (rhabdomyolysis, burns, trauma)
  • Use of K-sparing diuretics
  • Excess K supplementation
  • Comorbid conditions: CKD, diabetes, heart failure, liver disease

General Prevention

Low K diet and oral supplement compliance in those at risk

Commonly Associated Conditions

  • Acute kidney injury (AKI) or CKD, typically with GFR <30 mL/min
  • Congestive heart failure; myocardial infarction
  • Rhabdomyolysis
  • Liver disease
  • Use of offending medications

There's more to see -- the rest of this topic is available only to subscribers.